H04.149 Primary lacrimal gland atrophy, unspecified lacrimal gland

Name of the Condition

• Primary Lacrimal Gland Atrophy, Unspecified Lacrimal Gland (ICD-10 code: H04.149)

Summary

Primary lacrimal gland atrophy, unspecified lacrimal gland, is a condition involving the progressive degeneration or shrinkage of the lacrimal gland, which is responsible for tear production. This can lead to reduced tear output, resulting in dry eye symptoms or ocular discomfort. The term "primary" indicates the atrophy occurs without an identifiable underlying cause, distinguishing it from secondary atrophy linked to other diseases or trauma. The "unspecified" designation means the affected gland is not specified as right or left.

Causes

The exact cause of primary lacrimal gland atrophy is not fully understood. It is thought to involve age-related changes, autoimmune processes, or degenerative mechanisms affecting the gland tissue. Unlike secondary atrophy, no specific infection, trauma, or systemic disease is identified as the trigger in primary cases.

Risk Factors

Risk factors may include advanced age, as glandular tissue naturally declines over time. Genetic predisposition or a history of autoimmune conditions could also increase susceptibility, though specific associations are not well established for primary cases.

Symptoms

Symptoms typically include persistent dryness, burning, or grittiness in the eyes. Patients may experience reduced tear production, leading to discomfort, redness, or a sensation of foreign bodies. Vision may be temporarily blurred due to inadequate lubrication.

Diagnosis

Diagnosis involves a clinical evaluation, including a review of symptoms and ocular examination. Tests such as Schirmer’s test (to measure tear production) or imaging studies (e.g., MRI or CT) may be used to assess gland structure. The absence of an identifiable underlying cause supports a primary diagnosis.

Treatment Options

Treatment focuses on managing symptoms, such as using artificial tears, lubricating ointments, or anti-inflammatory medications. In some cases, punctal plugs may be inserted to retain natural tears. Underlying autoimmune conditions, if present, may require immunosuppressive therapy.

Prognosis and Follow-Up

Prognosis depends on the severity of gland atrophy and response to treatment. Regular follow-up with an ophthalmologist is recommended to monitor tear production and adjust therapies as needed. Early intervention can help prevent complications like corneal damage.

Complications

Complications may include chronic dry eye, corneal abrasions, or infections due to insufficient tear film. Severe cases can lead to vision impairment if left untreated.

Lifestyle & Prevention

Lifestyle measures include avoiding dry environments, using humidifiers, and protecting eyes from wind or irritants. Smoking cessation and a balanced diet rich in omega-3 fatty acids may support ocular health, though these do not prevent atrophy.

When to Seek Professional Help

Seek care if dry eye symptoms persist, worsen, or are accompanied by pain, redness, or vision changes. Prompt evaluation is important to rule out other conditions and initiate appropriate management.

Tips for Medical Coders

Use H04.149 for primary lacrimal gland atrophy when the affected gland is not specified as right or left. Document the absence of secondary causes (e.g., trauma, infection, or systemic disease) to support the "primary" designation. Ensure clinical notes align with the unspecified nature of the gland to justify code selection.